{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:02:32Z","timestamp":1794204152231,"version":"4.8.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health","award":["R01AR071653"],"award-info":[{"award-number":["R01AR071653"]}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX005921-01"],"award-info":[{"award-number":["BX005921-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dermatomyositis (DM) is an infrequently encountered idiopathic inflammatory myopathy distinguished by distinctive cutaneous manifestations and\/or progressive muscle weakness. This review provides an updated exploration of DM, emphasizing cutaneous features, etiopathogenesis, and therapeutic implications. DM presents a heterogeneous spectrum, ranging from classic forms involving both skin and muscle to clinically amyopathic DM, which lacks significant muscle involvement but carries risks like interstitial lung disease (ILD) and malignancy. Recent advances in understanding DM pathogenesis underscore the roles of myositis-specific autoantibodies, type I interferons, and cytokine dysregulation in disease activity and clinical outcomes. Specific antibodies such as anti-Mi-2, anti-TIF1\u03b3, and anti-MDA5 define subtypes of DM, aiding diagnosis, prognosis, and tailored management strategies. While conventional immunosuppressive therapies like glucocorticoids and antimalarials form the cornerstone of treatment, many cases remain refractory, particularly involving chronic skin disease. Emerging targeted therapies, including Janus kinase inhibitors and monoclonal antibodies, show promise in addressing type I interferon-driven pathways and refractory symptoms. Future research aims to refine diagnostic criteria, integrate biomarkers, utilize more robust outcome measures, and develop targeted therapeutics to improve outcomes while minimizing treatment-related toxicity. This review consolidates current knowledge and highlights the need for a multidisciplinary, individualized approach to managing DM, focusing on both established and novel treatment avenues.<\/jats:p>","DOI":"10.1007\/s00281-025-01054-9","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:52:44Z","timestamp":1754495564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-480X","authenticated-orcid":false,"given":"Hammad","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3221-5391","authenticated-orcid":false,"given":"Aretha","family":"On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enze","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"7","key":"1054_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975a) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344\u2013347","journal-title":"N Engl J Med"},{"issue":"8","key":"1054_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975b) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403\u2013407","journal-title":"N Engl J Med"},{"issue":"4","key":"1054_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46(4):626\u2013636","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1054_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nrrheum.2011.139","volume":"7","author":"AB Robinson","year":"2011","unstructured":"Robinson AB, Reed AM (2011) Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 7(11):664\u2013675","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1054_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.21037\/atm-20-5175","volume":"9","author":"LM Hodgkinson","year":"2021","unstructured":"Hodgkinson LM, Wu TT, Fiorentino DF (2021) Dermatomyositis autoantibodies: how can we maximize utility? Ann Transl Med 9(5):433","journal-title":"Ann Transl Med"},{"issue":"12","key":"1054_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","volume":"19","author":"AGS Oldroyd","year":"2023","unstructured":"Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P et al (2023) International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol 19(12):805\u2013817","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1054_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaad.2017.12.074","volume":"79","author":"DM Da Silva","year":"2018","unstructured":"Da Silva DM, Patel B, Werth VP (2018) Dermatomyositis: a diagnostic dilemma. J Am Acad Dermatol 79(2):371\u2013373","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1054_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2020.02.061","volume":"83","author":"K Bowerman","year":"2020","unstructured":"Bowerman K, Pearson DR, Okawa J, Werth VP (2020) Malignancy in dermatomyositis: a retrospective study of 201 patients seen at the University of Pennsylvania. J Am Acad Dermatol 83(1):117\u2013122","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1054_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjd.14771","volume":"176","author":"MD George","year":"2017","unstructured":"George MD, Shah R, Kreider M, Miller WT Jr, Merkel PA, Werth VP (2017) Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis. Br J Dermatol 176(1):262\u2013264","journal-title":"Br J Dermatol"},{"issue":"2","key":"1054_CR10","first-page":"359","volume":"41","author":"D Lim","year":"2023","unstructured":"Lim D, Fiorentino D, Werth V (2023) Current concepts and advances in dermatomyositis: a dermatological perspective. Clin Exp Rheumatol 41(2):359\u2013369","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1054_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaad.2024.02.007","volume":"91","author":"R Pandya","year":"2024","unstructured":"Pandya R, Kleitsch J, Lim D, Werth VP (2024) Clinical characteristics and symptom progression of dermatomyositis subtypes: A retrospective analysis of a prospective database. J Am Acad Dermatol 91(1):31\u201336","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1054_CR12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M et al (2017) 2017 European league against Rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76(12):1955\u20131964","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1054_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjd.18096","volume":"182","author":"JSS Concha","year":"2020","unstructured":"Concha JSS, Pena S, Gaffney RG, Patel B, Tarazi M, Kushner CJ et al (2020) Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. Br J Dermatol 182(2):410\u2013417","journal-title":"Br J Dermatol"},{"issue":"1","key":"1054_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","volume":"79","author":"B Patel","year":"2018","unstructured":"Patel B, Khan N, Werth VP (2018) Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease. J Am Acad Dermatol 79(1):77-83 e1","journal-title":"J Am Acad Dermatol"},{"issue":"34","key":"1054_CR15","doi-asserted-by":"publisher","first-page":"e21733","DOI":"10.1097\/MD.0000000000021733","volume":"99","author":"L Chang","year":"2020","unstructured":"Chang L, Zhang L, Jia H, Nie Z, Zhang L (2020) Malignancy in dermatomyositis: a retrospective paired case-control study of 202 patients from Central China. Medicine 99(34):e21733","journal-title":"Medicine"},{"key":"1054_CR16","doi-asserted-by":"publisher","unstructured":"Pandya R, Dan J, Kleitsch J, Lim D, White B, Werth VP (2024) Development and evaluation of the dermatomyositis outcomes for muscle and skin as an outcome measure in dermatomyositis clinical trials. JID Innov 5(2):100337. https:\/\/doi.org\/10.1016\/j.xjidi.2024.100337","DOI":"10.1016\/j.xjidi.2024.100337"},{"issue":"3","key":"1054_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J Am Acad Dermatol 72(3):449\u2013455","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1054_CR18","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/1346-8138.15049","volume":"46","author":"H Fukamatsu","year":"2019","unstructured":"Fukamatsu H, Hirai Y, Miyake T, Kaji T, Morizane S, Yokoyama E et al (2019) Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies. J Dermatol 46(10):886\u2013897","journal-title":"J Dermatol"},{"issue":"1","key":"1054_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.14801","volume":"176","author":"CC Ang","year":"2017","unstructured":"Ang CC, Anyanwu CO, Robinson E, Okawa J, Feng R, Fujimoto M et al (2017) Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis. Br J Dermatol 176(1):231\u2013233","journal-title":"Br J Dermatol"},{"issue":"2","key":"1054_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/acr.24786","volume":"75","author":"VL Kronzer","year":"2023","unstructured":"Kronzer VL, Kimbrough BA, Crowson CS, Davis JM 3rd, Holmqvist M, Ernste FC (2023) Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res 75(2):348\u2013355","journal-title":"Arthritis Care Res"},{"key":"1054_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fmed.2019.00085","volume":"6","author":"DR Pearson","year":"2019","unstructured":"Pearson DR, Werth VP (2019) Geospatial correlation of amyopathic dermatomyositis with fixed sources of airborne pollution: a retrospective cohort study. Front Med (Lausanne) 6:85","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"1054_CR22","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/ard.2008.093161","volume":"68","author":"S Bernatsky","year":"2009","unstructured":"Bernatsky S, Joseph L, Pineau CA, Belisle P, Boivin JF, Banerjee D et al (2009) Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis 68(7):1192\u20131196","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1054_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13075-018-1617-9","volume":"20","author":"JE Parkes","year":"2018","unstructured":"Parkes JE, Rothwell S, Oldroyd A, Chinoy H, Lamb JA, Myositis GC (2018) Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-gamma autoantibodies in adult patients with myositis. Arthritis Res Ther 20(1):117","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1054_CR24","doi-asserted-by":"publisher","first-page":"105308","DOI":"10.1016\/j.jbspin.2021.105308","volume":"89","author":"S Bowman","year":"2022","unstructured":"Bowman S, Lu H (2022) Aromatase inhibitor-induced inflammatory myopathies: A case series. Joint Bone Spine 89(2):105308","journal-title":"Joint Bone Spine"},{"issue":"4","key":"1054_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","volume":"85","author":"HT Quach","year":"2021","unstructured":"Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK (2021) Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol 85(4):956\u2013966","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1054_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamadermatol.2023.5418","volume":"160","author":"S Caravan","year":"2024","unstructured":"Caravan S, Lopez CM, Yeh JE (2024) Causes and clinical presentation of drug-induced dermatomyositis: a systematic review. JAMA Dermatol 160(2):210\u2013217","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1054_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJM199208273270919","volume":"327","author":"BB Schalke","year":"1992","unstructured":"Schalke BB, Schmidt B, Toyka K, Hartung HP (1992) Pravastatin-associated inflammatory myopathy. N Engl J Med 327(9):649\u2013650","journal-title":"N Engl J Med"},{"issue":"7","key":"1054_CR28","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","volume":"146","author":"R Klein","year":"2010","unstructured":"Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146(7):780\u2013784","journal-title":"Arch Dermatol"},{"issue":"1","key":"1054_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.autrev.2013.08.005","volume":"13","author":"JP Stubgen","year":"2014","unstructured":"Stubgen JP (2014) A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev 13(1):31\u201339","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1054_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/acr.25236","volume":"76","author":"M Diaz-Menindez","year":"2024","unstructured":"Diaz-Menindez M, Sullivan MM, Wang B, Majithia V, Abril A, Butendieck RR Jr et al (2024) Dermatomyositis in association with SARS-CoV-2 infection or COVID-19 vaccine. Arthritis Care Res 76(1):98\u2013104","journal-title":"Arthritis Care Res"},{"key":"1054_CR31","doi-asserted-by":"publisher","first-page":"899526","DOI":"10.3389\/fimmu.2022.899526","volume":"13","author":"G Sprow","year":"2022","unstructured":"Sprow G, Afarideh M, Dan J, Feng R, Keyes E, Grinnell M et al (2022) Autoimmune skin disease exacerbations following COVID-19 vaccination. Front Immunol 13:899526","journal-title":"Front Immunol"},{"issue":"3","key":"1054_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jaad.2018.08.019","volume":"80","author":"M Zeidi","year":"2019","unstructured":"Zeidi M, Chansky PB, Werth VP (2019) Acute onset\/flares of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings. J Am Acad Dermatol 80(3):801\u2013804","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1054_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1001\/archderm.140.6.723","volume":"140","author":"AN Lee","year":"2004","unstructured":"Lee AN, Werth VP (2004) Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol 140(6):723\u2013727","journal-title":"Arch Dermatol"},{"issue":"1","key":"1054_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13075-022-02843-5","volume":"24","author":"N Zhao","year":"2022","unstructured":"Zhao N, Smargiassi A, Jean S, Gamache P, Laouan-Sidi EA, Chen H et al (2022) Long-term exposure to fine particulate matter and ozone and the onset of systemic autoimmune rheumatic diseases: an open cohort study in Quebec, Canada. Arthritis Res Ther 24(1):151","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1054_CR35","doi-asserted-by":"publisher","first-page":"2312241","DOI":"10.1080\/09546634.2024.2312241","volume":"35","author":"L Lopes Almeida Gomes","year":"2024","unstructured":"Lopes Almeida Gomes L, Werth AJ, Thomas P, Werth VP (2024) The impact of hormones in autoimmune cutaneous diseases. J Dermatolog Treat 35(1):2312241","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1054_CR36","first-page":"45","volume":"15","author":"LA Dourmishev","year":"2006","unstructured":"Dourmishev LA, Wollina U (2006) Dermatomyositis: immunopathologic study of skin lesions. Acta Dermatovenerol Alp Pannonica Adriat 15(1):45\u201351","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"1054_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1159\/000131751","volume":"10","author":"MS Krathen","year":"2008","unstructured":"Krathen MS, Fiorentino D, Werth VP (2008) Dermatomyositis. Curr Dir Autoimmun 10:313\u2013332","journal-title":"Curr Dir Autoimmun"},{"issue":"2 Pt 1","key":"1054_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0190-9622(91)70186-6","volume":"25","author":"G Hausmann","year":"1991","unstructured":"Hausmann G, Herrero C, Cid MC, Casademont J, Lecha M, Mascaro JM (1991) Immunopathologic study of skin lesions in dermatomyositis. J Am Acad Dermatol 25(2 Pt 1):225\u2013230","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1054_CR39","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1365-2133.2004.06144.x","volume":"151","author":"M Caproni","year":"2004","unstructured":"Caproni M, Torchia D, Cardinali C, Volpi W, Del Bianco E, D\u2019Agata A et al (2004) Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol 151(4):784\u2013791","journal-title":"Br J Dermatol"},{"issue":"4","key":"1054_CR40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","volume":"31","author":"J Wenzel","year":"2006","unstructured":"Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tuting T (2006) Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 31(4):576\u2013582","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1054_CR41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1600-0560.2007.00848.x","volume":"35","author":"JM McNiff","year":"2008","unstructured":"McNiff JM, Kaplan DH (2008) Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol 35(5):452\u2013456","journal-title":"J Cutan Pathol"},{"issue":"9","key":"1054_CR42","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.jid.2021.02.748","volume":"141","author":"J Patel","year":"2021","unstructured":"Patel J, Maddukuri S, Li Y, Bax C, Werth VP (2021) Highly Multiplexed Mass Cytometry Identifies the Immunophenotype in the Skin of Dermatomyositis. J Invest Dermatol 141(9):2151\u20132160","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1054_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjd.16498","volume":"179","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Zeidi M, Bonciani D, Pena SM, Tiao J, Sahu S et al (2018) Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol 179(3):669\u2013678","journal-title":"Br J Dermatol"},{"key":"1054_CR44","doi-asserted-by":"publisher","first-page":"854848","DOI":"10.3389\/fimmu.2022.854848","volume":"13","author":"P Huang","year":"2022","unstructured":"Huang P, Tang L, Zhang L, Ren Y, Peng H, Xiao Y et al (2022) Identification of biomarkers associated with CD4(+) T-cell infiltration with gene coexpression network in dermatomyositis. Front Immunol 13:854848","journal-title":"Front Immunol"},{"issue":"4","key":"1054_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jaut.2010.07.006","volume":"35","author":"E Antiga","year":"2010","unstructured":"Antiga E, Kretz CC, Klembt R, Massi D, Ruland V, Stumpf C et al (2010) Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun 35(4):342\u2013350","journal-title":"J Autoimmun"},{"issue":"3","key":"1054_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/ket279","volume":"53","author":"P Venalis","year":"2014","unstructured":"Venalis P, Lundberg IE (2014) Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology 53(3):397\u2013405","journal-title":"Rheumatology"},{"issue":"2","key":"1054_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410160206","volume":"16","author":"K Arahata","year":"1984","unstructured":"Arahata K, Engel AG (1984) Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 16(2):193\u2013208","journal-title":"Ann Neurol"},{"issue":"6","key":"1054_CR48","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/ard.2008.091405","volume":"68","author":"O Krystufkova","year":"2009","unstructured":"Krystufkova O, Vallerskog T, Helmers SB, Mann H, Putova I, Belacek J et al (2009) Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 68(6):836\u2013843","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1054_CR49","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jid.2024.07.007","volume":"145","author":"M Ogawa-Momohara","year":"2025","unstructured":"Ogawa-Momohara M, Vazquez T, Chin F, Sharma M, Dan J, Sprow G, Werth VP (2025) Multiplexed Mass cytometry of cutaneous lupus erythematosus and dermatomyositis skin: an In-depth. B-Cell-Directed Immunoprofile. J Invest Dermato 145(1):190\u2013193. https:\/\/doi.org\/10.1016\/j.jid.2024.07.007","journal-title":"B-Cell-Directed Immunoprofile. J Invest Dermato"},{"issue":"3","key":"1054_CR50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0046-8177(89)90128-7","volume":"20","author":"AM Emslie-Smith","year":"1989","unstructured":"Emslie-Smith AM, Arahata K, Engel AG (1989) Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 20(3):224\u2013231","journal-title":"Hum Pathol"},{"issue":"5","key":"1054_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R et al (2005) Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57(5):664\u2013678","journal-title":"Ann Neurol"},{"issue":"3","key":"1054_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/gene.2011.61","volume":"13","author":"SA Greenberg","year":"2012","unstructured":"Greenberg SA, Higgs BW, Morehouse C, Walsh RJ, Kong SW, Brohawn P et al (2012) Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 13(3):207\u2013213","journal-title":"Genes Immun"},{"issue":"1","key":"1054_CR53","doi-asserted-by":"publisher","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","volume":"7","author":"D Wong","year":"2012","unstructured":"Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P et al (2012) Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS ONE 7(1):e29161","journal-title":"PLoS ONE"},{"issue":"5","key":"1054_CR54","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/ard.2010.139949","volume":"70","author":"AP Liao","year":"2011","unstructured":"Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA (2011) Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 70(5):831\u2013836","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1054_CR55","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"Huard C, Gulla SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA (2017) Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br J Dermatol 176(5):1224\u20131230","journal-title":"Br J Dermatol"},{"key":"1054_CR56","doi-asserted-by":"publisher","first-page":"1214920","DOI":"10.3389\/fmed.2024.1214920","volume":"11","author":"R Raupov","year":"2024","unstructured":"Raupov R, Suspitsin E, Preobrazhenskaya EV, Kostik M (2024) Interferon type I signature associated with skin disease in juvenile dermatomyositis. Front Med (Lausanne) 11:1214920","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"1054_CR57","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/art.42526","volume":"75","author":"MM Tabata","year":"2023","unstructured":"Tabata MM, Hodgkinson LM, Wu TT, Li S, Huard C, Zhao S et al (2023) The Type I Interferon Signature Reflects Multiple Phenotypic and Activity Measures in Dermatomyositis. Arthritis Rheumatol 75(10):1842\u20131849","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1054_CR58","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/cup.13880","volume":"48","author":"M Zeidi","year":"2021","unstructured":"Zeidi M, Chen KL, Patel B, Ravishankar A, Lim R, Werth VP (2021) Increased MxA protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a single-center case-control study. J Cutan Pathol 48(3):364\u2013373","journal-title":"J Cutan Pathol"},{"issue":"6","key":"1054_CR59","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1600-0560.2009.01443.x","volume":"37","author":"CM Magro","year":"2010","unstructured":"Magro CM, Segal JP, Crowson AN, Chadwick P (2010) The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol 37(6):659\u2013671","journal-title":"J Cutan Pathol"},{"key":"1054_CR60","doi-asserted-by":"publisher","unstructured":"Tsoi LC, Gharaee-Kermani M, Berthier CC, Nault T, Hile GA, Estadt SN, Patrick MT, Wasikowski R, Billi AC, Lowe L, Reed TJ (2020) IL18-containing 5-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions. JCI Insight 5(16):e139558. https:\/\/doi.org\/10.1172\/jci.insight.139558","DOI":"10.1172\/jci.insight.139558"},{"issue":"8","key":"1054_CR61","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.jid.2020.12.032","volume":"141","author":"KL Chen","year":"2021","unstructured":"Chen KL, Patel J, Zeidi M, Wysocka M, Bashir MM, Patel B et al (2021) Myeloid dendritic cells are major producers of IFN-beta in dermatomyositis and may contribute to hydroxychloroquine refractoriness. J Invest Dermatol 141(8):1906\u201314 e2","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1054_CR62","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","volume":"11","author":"A Psarras","year":"2020","unstructured":"Psarras A, Alase A, Antanaviciute A, Carr IM, Md Yusof MY, Wittmann M et al (2020) Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat Commun 11(1):6149","journal-title":"Nat Commun"},{"issue":"5","key":"1054_CR63","doi-asserted-by":"publisher","first-page":"434","DOI":"10.21037\/atm-20-3719","volume":"9","author":"CE Bax","year":"2021","unstructured":"Bax CE, Maddukuri S, Ravishankar A, Pappas-Taffer L, Werth VP (2021) Environmental triggers of dermatomyositis: a narrative review. Ann Transl Med 9(5):434","journal-title":"Ann Transl Med"},{"issue":"4","key":"1054_CR64","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.amjms.2020.05.011","volume":"360","author":"R Peravali","year":"2020","unstructured":"Peravali R, Acharya S, Raza SH, Pattanaik D, Randall MB (2020) Dermatomyositis developed after exposure to epstein-barr virus infection and antibiotics use. Am J Med Sci 360(4):402\u2013405","journal-title":"Am J Med Sci"},{"issue":"1","key":"1054_CR65","doi-asserted-by":"publisher","first-page":"2220984","DOI":"10.1080\/08916934.2023.2220984","volume":"56","author":"Y Yang","year":"2023","unstructured":"Yang Y, Song J, Zhao H, Zhang H, Guo M (2023) Patients with dermatomyositis shared partially similar transcriptome signature with COVID-19 infection. Autoimmunity 56(1):2220984","journal-title":"Autoimmunity"},{"issue":"4","key":"1054_CR66","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2020.05.051","volume":"84","author":"Y Kuriyama","year":"2021","unstructured":"Kuriyama Y, Shimizu A, Kanai S, Oikawa D, Tokunaga F, Tsukagoshi H et al (2021) The synchronized gene expression of retrotransposons and type I interferon in dermatomyositis. J Am Acad Dermatol 84(4):1103\u20131105","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1054_CR67","doi-asserted-by":"publisher","first-page":"23146","DOI":"10.1038\/s41598-021-02522-6","volume":"11","author":"Y Kuriyama","year":"2021","unstructured":"Kuriyama Y, Shimizu A, Kanai S, Oikawa D, Motegi SI, Tokunaga F et al (2021) Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease. Sci Rep 11(1):23146","journal-title":"Sci Rep"},{"issue":"5","key":"1054_CR68","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jaad.2021.12.050","volume":"87","author":"A Ravishankar","year":"2022","unstructured":"Ravishankar A, Bax CE, Grinnell M, Yan D, Concha JS, Pappas-Taffer L et al (2022) Frequency of immunostimulatory herbal supplement use among patients with autoimmune skin disease. J Am Acad Dermatol 87(5):1093\u20131095","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1054_CR69","doi-asserted-by":"publisher","first-page":"108355","DOI":"10.1016\/j.isci.2023.108355","volume":"26","author":"CE Bax","year":"2023","unstructured":"Bax CE, Diaz D, Li Y, Vazquez T, Patel J, Grinnell M et al (2023) Herbal supplement Spirulina stimulates inflammatory cytokine production in patients with dermatomyositis in vitro. IScience 26(11):108355","journal-title":"IScience"},{"issue":"15","key":"1054_CR70","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.7150\/thno.59152","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Bax C, Patel J, Vazquez T, Ravishankar A, Bashir MM et al (2021) Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis. Theranostics 11(15):7144\u20137158","journal-title":"Theranostics"},{"issue":"11","key":"1054_CR71","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/art.24936","volume":"60","author":"H Bilgic","year":"2009","unstructured":"Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T et al (2009) Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60(11):3436\u20133446","journal-title":"Arthritis Rheum"},{"key":"1054_CR72","doi-asserted-by":"publisher","first-page":"1168359","DOI":"10.3389\/fmed.2023.1168359","volume":"10","author":"A Vincze","year":"2023","unstructured":"Vincze A, Herczeg-Lisztes E, Szabo K, Beldi TG, Nagy-Vincze M, Por A et al (2023) Pruritogenic molecules in the skin of patients with dermatomyositis. Front Med (Lausanne) 10:1168359","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1054_CR73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/mr\/roac147","volume":"34","author":"D Li","year":"2023","unstructured":"Li D, Jia W, Zhou L, Hao Y, Wang K, Yang B et al (2023) Increased expression of the p-STAT3\/IL-17 signaling pathway in patients with dermatomyositis. Mod Rheumatol 34(1):129\u2013136","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1054_CR74","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/cei.12311","volume":"177","author":"T Fujiyama","year":"2014","unstructured":"Fujiyama T, Ito T, Ogawa N, Suda T, Tokura Y, Hashizume H (2014) Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis. Clin Exp Immunol 177(1):110\u2013120","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1054_CR75","first-page":"656","volume":"37","author":"MG Silva","year":"2019","unstructured":"Silva MG, Oba-Shinjo SM, Marie SKN, Shinjo SK (2019) Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 37(4):656\u2013662","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"1054_CR76","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/rheumatology\/key222","volume":"57","author":"SB Helmers","year":"2018","unstructured":"Helmers SB, Bruton M, Loell I, Ulfgren AK, Gracie AJ, McInnes IB et al (2018) Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment. Rheumatology (Oxford) 57(12):2149\u20132157","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1054_CR77","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1128\/IAI.00401-15","volume":"83","author":"AK Syed","year":"2015","unstructured":"Syed AK, Reed TJ, Clark KL, Boles BR, Kahlenberg JM (2015) Staphlyococcus aureus phenol-soluble modulins stimulate the release of proinflammatory cytokines from keratinocytes and are required for induction of skin inflammation. Infect Immun 83(9):3428\u20133437","journal-title":"Infect Immun"},{"issue":"4","key":"1054_CR78","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0889-857X(02)00025-X","volume":"28","author":"IE Lundberg","year":"2002","unstructured":"Lundberg IE, Dastmalchi M (2002) Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am 28(4):799\u2013822","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"1054_CR79","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1523-1747.2002.01869.x","volume":"119","author":"VP Werth","year":"2002","unstructured":"Werth VP, Callen JP, Ang G, Sullivan KE (2002) Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 119(3):617\u2013620","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1054_CR80","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","volume":"140","author":"C Cassius","year":"2020","unstructured":"Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A et al (2020) MDA5(+) dermatomyositis is associated with stronger skin type i interferon transcriptomic signature with upregulation of IFN-kappa transcript. J Invest Dermatol 140(6):1276\u20131279","journal-title":"J Invest Dermatol"},{"key":"1054_CR81","doi-asserted-by":"publisher","first-page":"1249844","DOI":"10.3389\/fimmu.2023.1249844","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jia H, Li W, Liu H, Tu M, Li J et al (2023) Transcriptomic profiling and longitudinal study reveal the relationship of anti-MDA5 titer and type I IFN signature in MDA5+ dermatomyositis. Front Immunol 14:1249844","journal-title":"Front Immunol"},{"key":"1054_CR82","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.jaut.2022.102831","volume":"130","author":"F Coutant","year":"2022","unstructured":"Coutant F, Bachet R, Pin JJ, Alonzo M, Miossec P (2022) Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production. J Autoimmun 130:102831","journal-title":"J Autoimmun"},{"issue":"2","key":"1054_CR83","first-page":"203","volume":"14","author":"W Ericson-Neilsen","year":"2014","unstructured":"Ericson-Neilsen W, Kaye AD (2014) Steroids: pharmacology, complications, and practice delivery issues. Ochsner J 14(2):203\u2013207","journal-title":"Ochsner J"},{"issue":"10","key":"1054_CR84","first-page":"829","volume":"8","author":"FR Ochsendorf","year":"2010","unstructured":"Ochsendorf FR (2010) Use of antimalarials in dermatology. J Dtsch Dermatol Ges 8(10):829\u201344; quiz 45","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"1054_CR85","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1191\/0961203302lu147rr","volume":"11","author":"A Wozniacka","year":"2002","unstructured":"Wozniacka A, Carter A, McCauliffe DP (2002) Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 11(2):71\u201381","journal-title":"Lupus"},{"issue":"3","key":"1054_CR86","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ad.2012.10.005","volume":"105","author":"C Rodriguez-Caruncho","year":"2014","unstructured":"Rodriguez-Caruncho C, Bielsa MI (2014) Antimalarials in dermatology: mechanism of action, indications, and side effects. Actas Dermosifiliogr 105(3):243\u2013252","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"1054_CR87","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jisp.2016.11.001","volume":"18","author":"P Alves","year":"2017","unstructured":"Alves P, Bashir MM, Wysocka M, Zeidi M, Feng R, Werth VP (2017) Quinacrine suppresses tumor necrosis factor-alpha and ifn-alpha in dermatomyositis and cutaneous lupus erythematosus. J Investig Dermatol Symp Proc 18(2):S57\u2013S63","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"4","key":"1054_CR88","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0190-9622(84)80263-7","volume":"10","author":"TY Woo","year":"1984","unstructured":"Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C (1984) Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 10(4):592\u2013600","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1054_CR89","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","volume":"3","author":"CO Anyanwu","year":"2017","unstructured":"Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP (2017) The systemic management of cutaneous dermatomyositis: results of a stepwise strategy. Int J Womens Dermatol 3(4):189\u2013194","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"1054_CR90","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jaad.2017.09.061","volume":"78","author":"L Mittal","year":"2018","unstructured":"Mittal L, Zhang L, Feng R, Werth VP (2018) Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. J Am Acad Dermatol 78(1):100\u20136 e1","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1054_CR91","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/art.41683","volume":"73","author":"JT Rosenbaum","year":"2021","unstructured":"Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM et al (2021) American college of rheumatology, american academy of dermatology, rheumatologic dermatology society, and american academy of ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthritis Rheumatol 73(6):908\u2013911","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1054_CR92","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/archderm.141.7.855","volume":"141","author":"GC Ang","year":"2005","unstructured":"Ang GC, Werth VP (2005) Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 141(7):855\u2013859","journal-title":"Arch Dermatol"},{"issue":"4","key":"1054_CR93","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jaad.2020.07.081","volume":"84","author":"A Ravishankar","year":"2021","unstructured":"Ravishankar A, Yan D, Bax CE, Concha JS, Feng R, Werth VP (2021) Response of dermatomyositis to the antimalarial quinacrine: a retrospective cohort study. J Am Acad Dermatol 84(4):1157\u20131160","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1054_CR94","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"B Friedman","year":"2019","unstructured":"Friedman B, Cronstein B (2019) Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine 86(3):301\u2013307","journal-title":"Joint Bone Spine"},{"issue":"5 Pt 1","key":"1054_CR95","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/0190-9622(95)91455-2","volume":"32","author":"ME Zieglschmid-Adams","year":"1995","unstructured":"Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD (1995) Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 32(5 Pt 1):754\u2013757","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1054_CR96","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","volume":"56","author":"A Bohan","year":"1977","unstructured":"Bohan A, Peter JB, Bowman RL, Pearson CM (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56(4):255\u2013286","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1054_CR97","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.21235","volume":"187","author":"M Grinnell","year":"2022","unstructured":"Grinnell M, Keyes E, Diaz D, Vazquez T, Feng R, Werth VP (2022) Mycophenolate mofetil and methotrexate efficacy in dermatomyositis. Br J Dermatol 187(3):437\u2013438","journal-title":"Br J Dermatol"},{"issue":"2","key":"1054_CR98","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/0049-0172(90)90024-A","volume":"20","author":"G Ramirez","year":"1990","unstructured":"Ramirez G, Asherson RA, Khamashta MA, Cervera R, D\u2019Cruz D, Hughes GR (1990) Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 20(2):114\u2013120","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1054_CR99","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24(1):45\u201348","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1054_CR100","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar3704","volume":"14","author":"E Schiopu","year":"2012","unstructured":"Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC (2012) Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 14(1):R22","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1054_CR101","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s10067-011-1840-0","volume":"30","author":"KH Yu","year":"2011","unstructured":"Yu KH, Wu YJ, Kuo CF, See LC, Shen YM, Chang HC et al (2011) Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 30(12):1595\u20131601","journal-title":"Clin Rheumatol"},{"issue":"2\u20133","key":"1054_CR102","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2\u20133):85\u2013118","journal-title":"Immunopharmacology"},{"issue":"2","key":"1054_CR103","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jaad.2008.08.049","volume":"60","author":"AK Orvis","year":"2009","unstructured":"Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW (2009) Mycophenolate mofetil in dermatology. J Am Acad Dermatol 60(2):183\u201399; quiz 200-2","journal-title":"J Am Acad Dermatol"},{"key":"1054_CR104","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.7573\/dic.2020-8-8","volume":"10","author":"G Cassone","year":"2021","unstructured":"Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A (2021) Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context 10:2020\u20138. https:\/\/doi.org\/10.7573\/dic.2020-8-8","journal-title":"Drugs Context"},{"issue":"10","key":"1054_CR105","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","volume":"62","author":"PA Morganroth","year":"2010","unstructured":"Morganroth PA, Kreider ME, Werth VP (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res 62(10):1496\u20131501","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1054_CR106","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archderm.142.1.65","volume":"142","author":"JC Edge","year":"2006","unstructured":"Edge JC, Outland JD, Dempsey JR, Callen JP (2006) Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142(1):65\u201369","journal-title":"Arch Dermatol"},{"issue":"8","key":"1054_CR107","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","volume":"66","author":"J Rowin","year":"2006","unstructured":"Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN (2006) Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66(8):1245\u20131247","journal-title":"Neurology"},{"key":"1054_CR108","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejim.2023.01.018","volume":"110","author":"J Liao","year":"2023","unstructured":"Liao J, Peng X, Liu J, Xie X, Wang J (2023) The efficacy and safety of tacrolimus in patients with dermatomyositis\/polymyositis: A meta-analysis and systematic review. Eur J Intern Med 110:35\u201340","journal-title":"Eur J Intern Med"},{"issue":"5","key":"1054_CR109","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5021\/ad.24.022","volume":"36","author":"HJ Kim","year":"2024","unstructured":"Kim HJ, Werth VP (2024) Updates in dermatomyositis: newer treatment options and outcome measures from dermatologic perspectives. Ann Dermatol 36(5):257\u2013265","journal-title":"Ann Dermatol"},{"issue":"3","key":"1054_CR110","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5021\/ad.2011.23.3.348","volume":"23","author":"JE Kim","year":"2011","unstructured":"Kim JE, Jeong MG, Lee HE, Ko JY, Ro YS (2011) Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol 23(3):348\u2013351","journal-title":"Ann Dermatol"},{"issue":"2","key":"1054_CR111","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","volume":"127","author":"M Ballow","year":"2011","unstructured":"Ballow M (2011) The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 127(2):315\u201323; quiz 24-5","journal-title":"J Allergy Clin Immunol"},{"key":"1054_CR112","first-page":"674","volume":"5","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke SQ, Kuijpers TW (2014) Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol 5:674","journal-title":"Front Immunol"},{"issue":"5","key":"1054_CR113","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1994","unstructured":"Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94(5):1729\u20131735","journal-title":"J Clin Invest"},{"issue":"4","key":"1054_CR114","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.410270402","volume":"27","author":"AM Emslie-Smith","year":"1990","unstructured":"Emslie-Smith AM, Engel AG (1990) Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 27(4):343\u2013356","journal-title":"Ann Neurol"},{"issue":"Pt 7","key":"1054_CR115","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/brain\/aww122","volume":"139","author":"R Lahoria","year":"2016","unstructured":"Lahoria R, Selcen D, Engel AG (2016) Microvascular alterations and the role of complement in dermatomyositis. Brain 139(Pt 7):1891\u20131903","journal-title":"Brain"},{"issue":"Suppl 1","key":"1054_CR116","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1007\/s10875-014-0024-5","volume":"34","author":"MC Dalakas","year":"2014","unstructured":"Dalakas MC (2014) Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J Clin Immunol 34(Suppl 1):S120\u2013S126","journal-title":"J Clin Immunol"},{"key":"1054_CR117","doi-asserted-by":"publisher","first-page":"102234","DOI":"10.1016\/j.eclinm.2023.102234","volume":"64","author":"VP Werth","year":"2023","unstructured":"Werth VP, Aggarwal R, Charles-Schoeman C, Schessl J, Levine T, Kopasz N et al (2023) Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study. EClinicalMedicine 64:102234","journal-title":"EClinicalMedicine"},{"issue":"14","key":"1054_CR118","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csorgo Z, Dimachkie MM, Griger Z et al (2022) Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 387(14):1264\u20131278","journal-title":"N Engl J Med"},{"issue":"6","key":"1054_CR119","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"Ladislau L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M et al (2018) JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 141(6):1609\u20131621","journal-title":"Brain"},{"issue":"26","key":"1054_CR120","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J (2014) Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371(26):2537\u20132538","journal-title":"N Engl J Med"},{"issue":"5","key":"1054_CR121","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.41602","volume":"73","author":"JJ Paik","year":"2021","unstructured":"Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG et al (2021) Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol 73(5):858\u2013865","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1054_CR122","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381(3):291\u2013293","journal-title":"N Engl J Med"},{"key":"1054_CR123","doi-asserted-by":"publisher","unstructured":"Paik JJ, Vencovsk\u00fd J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, Mudd PN, Aggarwal R (2025) Brepocitinib, a potent and selective TYK2\/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol 43:354-63. https:\/\/doi.org\/10.55563\/clinexprheumatol\/eeglsa","DOI":"10.55563\/clinexprheumatol\/eeglsa"},{"issue":"6","key":"1054_CR124","first-page":"676","volume":"2","author":"P Boross","year":"2012","unstructured":"Boross P, Leusen JH (2012) Mechanisms of action of CD20 antibodies. Am J Cancer Res 2(6):676\u2013690","journal-title":"Am J Cancer Res"},{"issue":"2","key":"1054_CR125","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52(2):601\u2013607","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1054_CR126","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143(6):763\u2013767","journal-title":"Arch Dermatol"},{"issue":"2","key":"1054_CR127","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","volume":"56","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV (2017) Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology 56(2):247\u2013254","journal-title":"Rheumatology"},{"issue":"1","key":"1054_CR128","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73(1):256\u2013262","journal-title":"Ann Rheum Dis"},{"key":"1054_CR129","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","volume":"43","author":"PS Ang","year":"2024","unstructured":"Ang PS, Ezenwa E, Ko K, Hoffman MD (2024) Refractory dermatomyositis responsive to anifrolumab. JAAD Case Rep 43:27\u201329","journal-title":"JAAD Case Rep"},{"issue":"10473","key":"1054_CR130","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","volume":"405","author":"D Fiorentino","year":"2025","unstructured":"Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M et al (2025) Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 405(10473):137\u2013146","journal-title":"Lancet"},{"issue":"2","key":"1054_CR131","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/annrheumdis-2018-eular.6432","volume":"77","author":"R De Lorenzo","year":"2018","unstructured":"De Lorenzo R, Sciorati C, Monno A, Doglio MG, Rigamonti E, Ascherman D et al (2018) FRI0421 Toll like receptor-7\/8 activation exacerbates murine experimental autoimmune myositis. Ann Rheum Di 77(2):741","journal-title":"Ann Rheum Di"},{"issue":"2","key":"1054_CR132","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cpt.2606","volume":"112","author":"L Klopp-Schulze","year":"2022","unstructured":"Klopp-Schulze L, Shaw JV, Dong JQ, Khandelwal A, Vazquez-Mateo C, Goteti K (2022) Applying modeling and simulations for rational dose selection of novel toll-like receptor 7\/8 inhibitor enpatoran for indications of high medical need. Clin Pharmacol Ther 112(2):297\u2013306","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1054_CR133","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","volume":"142","author":"VP Werth","year":"2022","unstructured":"Werth VP, Hejazi E, Pena SM, Haber J, Zeidi M, Reddy N et al (2022) Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial. J Invest Dermatol 142(10):2651\u20132659","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1054_CR134","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.xjidi.2024.100311","volume":"5","author":"CJ Stone","year":"2025","unstructured":"Stone CJ, Ahuja G, Lopes Almeida Gomes L, Poroye J, Faden DF, Xie L et al (2025) Long-term safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: follow-up data from a 3-year open-label extension study. JID Innov. 5(1):100311","journal-title":"JID Innov."},{"issue":"Suppl 1","key":"1054_CR135","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/annrheumdis-2022-eular.5037","volume":"81","author":"V Werth","year":"2022","unstructured":"Werth V, White B, Dgetluck N, Hally K, Constantine S, Aggarwal R et al (2022) OP0162 efficacy and safety of lenabasum in the phase 3 determine trial in dermatomyositis. Ann Rheum Dis 81(Suppl 1):106\u2013107","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1054_CR136","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"issue":"24","key":"1054_CR137","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D et al (2023) CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154\u20132162","journal-title":"JAMA"},{"issue":"12","key":"1054_CR138","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","volume":"62","author":"S Julien","year":"2023","unstructured":"Julien S, van der Woning B, De Ceuninck L, Briand E, Jaworski T, Roussel G et al (2023) Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy. Rheumatology (Oxford) 62(12):4006\u20134011","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1054_CR139","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1600-0560.1997.tb01458.x","volume":"24","author":"CM Magro","year":"1997","unstructured":"Magro CM, Crowson AN (1997) The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus. J Cutan Pathol 24(9):543\u2013552","journal-title":"J Cutan Pathol"},{"issue":"12","key":"1054_CR140","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3899\/jrheum.180060","volume":"45","author":"S Faguer","year":"2018","unstructured":"Faguer S, Belliere J, Ribes D (2018) Complement C5-blocking agent in refractory dermatomyositis. J Rheumatol 45(12):1710\u20131711","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"1054_CR141","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/annrheumdis-2022-eular.1808","volume":"81","author":"L Cavagna","year":"2022","unstructured":"Cavagna L, Aggarwal R, Iikuni N, Rakhade S (2022) AB1287 design of a global phase 2\/3 randomized, placebo-controlled trial evaluating the efficacy and safety of ravulizumab in adults with dermatomyositis. Ann Rheum Dis 81(Suppl 1):1750\u20131751","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1054_CR142","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jaad.2021.05.026","volume":"86","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, Concha JSS, Chakka S, Krain RL, Zamalin D, Foulke G et al (2022) Diagnosing muscle disease in a cohort of classic dermatomyositis patients seen at a rheumatologic dermatology outpatient clinic. J Am Acad Dermatol 86(3):544\u2013550","journal-title":"J Am Acad Dermatol"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-025-01054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-025-01054-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-025-01054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:36:32Z","timestamp":1778672192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00281-025-01054-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s00281-025-01054-9","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VPW has grants from Celgene, Janssen, Pfizer, Biogen, Gilead, Corbus Pharmaceuticals, Genentech, AstraZeneca, Viela, Syntimmune, Amgen, Regeneron, Argenx, CSL Behring, Ventus, q32 Bio, BMS, Horizon and has consulted for Celgene, Genentech, Janssen, Lilly, Pfizer, Biogen, BMS, Gilead, Amgen, Medscape, Nektar, Incyte, EMD Sorona, CSL Behring, Principia, Crisalis, Viela Bio, Argenx, Kyowa Kirin, Regeneron, Principia, AstraZeneca, Abbvie, Octapharma, GSK, Astra-Zeneca, Cugene, UCB, Corcept, Beacon Bioscience, Rome Pharmaceuticals, Horizon, Gilead, Merck, Kezar, Sanofi, Bayer, Akari, Calyx, Cabaletta Bio. The University of Pennsylvania owns the copyright for the CLASI.The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"32"}}